Clinical Trial News and Research

RSS

University of Maryland surgeons transplant first lungs treated with experimental repair process

Surgeons at the University of Maryland Medical Center have transplanted the first lungs treated in the United States with an experimental repair process before transplantation. The procedure is part of a five-center national clinical research trial to evaluate the efficacy of repairing, before transplant, lungs that might otherwise have been passed over as unsuitable for organ donation.

8 Sep 2011

Aggressive medical management better than stenting for prevention of recurrent stroke

Patients at a high risk for a second stroke who received intensive medical treatment had fewer strokes and deaths than patients who received a brain stent in addition to the medical treatment, a large nationwide clinical trial has shown. The investigators published the results in today's online first edition of the New England Journal of Medicine.

8 Sep 2011

Enrollment complete in Concentric Medical's Stentriever trial for acute ischemic stroke

Concentric Medical, Inc., a global leader in acute ischemic stroke intervention, today announced completion of enrollment of the TREVO Study.

8 Sep 2011

Microvascular compression syndrome may cause Parkinson's

A potentially treatable blood vessel abnormality in the brain may be the cause of Parkinson's Disease in some patients, according to a study published today in the journal Neurology International by a team of leading physicians and neuroscientists at Pittsburgh's Allegheny General Hospital.

8 Sep 2011

OptiNose chooses BioClinica's advanced imaging and IWR solutions for clinical trials

BioClinica, Inc., a global provider of clinical trial management solutions, today announced that OptiNose, Inc. selected BioClinica Trident IWR, Optimizer clinical supplies forecasting, and Imaging Core Lab services for use in a series of clinical trials including several pivotal Phase III studies.

From Clario 8 Sep 2011

Aggressive medical treatment without stenting better for high-risk stroke patients

An article appearing in the Sept. 7 New England Journal of Medicine, reporting on National Institutes of Health research on brain stents, says aggressive medical treatment without stenting is better for high-risk stroke patients.

8 Sep 2011

AOI Medical receives ISO 13485 Certification and CE marking approval for two VCF devices

AOI Medical, Inc. has received ISO 13485 Certification and CE marking approval for its Ascendx VCF Repair System and its Ascendx Acu-Cut Vertebral Augmentation System to treat vertebral compression fractures (VCF).

8 Sep 2011

Researchers rethink fenretinide for prevention of oral cancer

Scientists on the cutting edge of biomedical research know that research is a process - a combination of successes and failures that inform the next step forward. However, for some researchers at The Ohio State University progress means taking a step back. Supported by the Ohio State University Center for Clinical and Translational Science (CCTS), these scientists are using failed and forgotten research to uncover future treatments for major health conditions as diverse as oral cancer and stroke.

7 Sep 2011

Top-line results from Auxilium XIAFLEX palpable cord study in Dupuytren's contracture subjects

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced positive top-line results from a pilot clinical study to assess safety, tolerability, and multiple-dose pharmacokinetics of XIAFLEX (collagenase clostridium histolyticum) in adult Dupuytren's contracture subjects with multiple palpable cords.

7 Sep 2011

Cancer Research UK opens olaparib-temozolomide combination Phase I trial in glioblastoma

Cancer Research UK's Drug Development Office has opened a trial of a new combination of drugs for the treatment of patients with brain cancer.

7 Sep 2011

ImmunoCellular provides update on ICT-107 Phase II trial for glioblastoma multiforme

ImmunoCellular Therapeutics, Ltd., a biotechnology company focused on the development of novel immune-based cancer therapies, provided an update today on clinical trial site activity and patient enrollment for its Phase II clinical trial of ICT-107, the Company's dendritic cell based cancer vaccine candidate targeting multiple tumor antigens for the treatment of glioblastoma multiforme.

7 Sep 2011

New bone marrow-derived stem cell therapy can benefit patients with degenerative disc disease

Neurosurgery researchers at UC Davis Health System have used a new, leading-edge stem cell therapy to promote the growth of bone tissue following the removal of cervical discs -- the cushions between the bones in the neck -- to relieve chronic, debilitating pain.

7 Sep 2011

St. Jude Medical's Genesis neurostimulation device receives European CE Mark approval

St. Jude Medical, Inc., a global medical device company, today announced it has received the industry's first and only regulatory approval for the use of an implanted neurostimulation device for patients with intractable chronic migraine.

7 Sep 2011

Leading cancer journals publish OncoGenex's custirsen pre-clinical and Phase II study data

OncoGenex Pharmaceuticals, Inc. announced today that data from two studies, a Phase II clinical study and a pre-clinical study, evaluating the investigational compound custirsen, were published in the September issues of the journals Clinical Cancer Research and Cancer Research.

7 Sep 2011

FDA stalls the blood-thinner Xarelto’s approval citing inadequate evidence

The Food and Drug Administration (FDA) said in a staff report released today that “there is insufficient information about the drug to determine whether it is safe for use with its proposed labeling.” Their report questions its safety and effectiveness, saying a new study is needed.

6 Sep 2011

Discovery Labs files Complete Response to FDA for SURFAXIN to treat RDS in premature infants

Discovery Labs, Inc. today announced that, on September 2, 2011, it submitted its Complete Response to the 2009 Complete Response Letter issued by the U.S. Food and Drug Administration (FDA) for SURFAXIN(lucinactant) for the prevention of respiratory distress syndrome (RDS) in premature infants.

6 Sep 2011

NanoLogix to move R&D operations from Cincinnati to its headquarters in Hubbard

NanoLogix, an innovator in the accelerated detection and identification of microorganisms, announced today it will move its research and development operations from Cincinnati to its headquarters in Hubbard, Ohio.

6 Sep 2011

NOXXON to commence NOX-H94 Phase I trial in anemia of chronic disease

NOXXON Pharma today announced the initiation of a Phase I clinical trial for NOX-H94, the Company's third compound to enter the clinic. NOX-H94 is a Spiegelmer designed to treat anemia of chronic disease by targeting the peptide hormone hepcidin, the key regulator of iron metabolism.

6 Sep 2011

Chondroitin sulfate decreases pain and improves hand function in patients with OA

New research shows that chondroitin sulfate significantly decreased pain and improved hand function in patients with osteoarthritis (OA) of the hand compared with those in the placebo group. Results of the clinical trial available today in Arthritis & Rheumatism, a journal published by Wiley-Blackwell on behalf of the American College of Rheumatology (ACR), also report that chondroitin sulfate improves grip strength and relieves morning stiffness.

6 Sep 2011

BioAlliance Pharma announces oral communication of Livatag Phase II trial results on liver cancer

BioAlliance Pharma SA, a company dedicated to specialty and orphan oncology products, today announces oral communication of the Phase II clinical trial results of its orphan product Livatag at the annual congress of ILCA, the only international organization devoted exclusively to liver cancer research with participation of worldwide best specialists.

6 Sep 2011

Clinical Trial News and Research

University of Maryland surgeons transplant first lungs treated with experimental repair process

Aggressive medical management better than stenting for prevention of recurrent stroke

Enrollment complete in Concentric Medical's Stentriever trial for acute ischemic stroke

Microvascular compression syndrome may cause Parkinson's

OptiNose chooses BioClinica's advanced imaging and IWR solutions for clinical trials

Aggressive medical treatment without stenting better for high-risk stroke patients

AOI Medical receives ISO 13485 Certification and CE marking approval for two VCF devices

Researchers rethink fenretinide for prevention of oral cancer

Top-line results from Auxilium XIAFLEX palpable cord study in Dupuytren's contracture subjects

Cancer Research UK opens olaparib-temozolomide combination Phase I trial in glioblastoma

ImmunoCellular provides update on ICT-107 Phase II trial for glioblastoma multiforme

New bone marrow-derived stem cell therapy can benefit patients with degenerative disc disease

St. Jude Medical's Genesis neurostimulation device receives European CE Mark approval

Leading cancer journals publish OncoGenex's custirsen pre-clinical and Phase II study data

FDA stalls the blood-thinner Xarelto’s approval citing inadequate evidence

Discovery Labs files Complete Response to FDA for SURFAXIN to treat RDS in premature infants

NanoLogix to move R&D operations from Cincinnati to its headquarters in Hubbard

NOXXON to commence NOX-H94 Phase I trial in anemia of chronic disease

Chondroitin sulfate decreases pain and improves hand function in patients with OA

BioAlliance Pharma announces oral communication of Livatag Phase II trial results on liver cancer

eBook: Using iPSCs models for human disease research and drug discovery eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer